Innoviva, Inc. (INVA)
Healthcare
- Fundamental
- 4
- Sentiment
- 2
- Technical
- 2
Do Nothing: qualitativeScore is 2 (below the required floor of 3) — the upstream qualitative screen flagged sharply deteriorating sentiment with no offsetting bullish catalyst, and the FST9 shadow branch is unavailable (shadow flag rendered false), so no bullish entry is admissible regardless of the chart. Independently, no entry qualifies on the technicals: a pullback/oversold limit is barred by the trend-alignment gate (price 18.97 < SMA50 20.75 with MACD -0.52 < 0, and price < SMA200 21.89 with SMA50 < SMA200 and no momentum reclaim), and a breakout stop above the 19.87/20.91 settled swing highs would give R/R ≈ 1.01 or worse against the 18.52 structural stop, at or below the 1.0 floor — buying into the 20.44/20.75 supply zone after an 11% six-session drawdown.
Company overview
Innoviva, Inc. is a pharmaceutical company focused on developing and marketing medical treatments globally. Its key products include combination therapies for respiratory conditions, such as RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA. The company collaborates with Glaxo Group Limited and Sarissa Capital Management LP.
Fundamental
goodInnoviva has strong cash generation and a robust balance sheet, but earnings quality and revenue concentration are concerns.
Innoviva pairs a fortress balance sheet (~$320M net cash, $581M in cash) and roughly $190M of annual operating cash flow with a declining GSK royalty base and very noisy GAAP earnings driven by Armata fair-value marks. Normalized earnings put the shares near 9-10x earnings and about 7x free cash flow. Solid underlying fundamentals with material concentration and earnings-quality caveats.
Sentiment
weakSentiment is weak with no positive catalysts, following a negative market reaction to recent earnings.
Dominant driver is the 2026-11-04 Q3 2026 print (announced confidence), received bearishly: revenue -1.6% to $106.1M, a $73.9M GAAP net loss and lower GSK royalties against an adjusted-EPS beat the tape did not reward, with the shares at a 52-week low four sessions later and a 12-month price target cut to $34.8 in between. The sentiment delta is indeterminate (the baseline window produced a single scorable on-topic item, a 2026-09-02 conference notice, far below the three-item threshold) and retail is indeterminate after a Reddit access block; no severe flag fired, but a moderate red-flag cap applied for sharply deteriorating sentiment with no offsetting bullish catalyst, which sets the ceiling rather than the level.
Technical
weakThe stock is in a downtrend below key moving averages, with negative momentum indicators.
Bearish-to-neutral chart with no base: price 18.97 sits below the SMA20 20.44, SMA50 20.75 and SMA200 21.89, and below EMA9 19.55, EMA21 20.16, WMA9 19.30 and WMA21 20.09, so the whole moving-average stack is overhead resistance. Momentum is negative and un-repaired — MACD line -0.52 is below its -0.29 signal and below zero with the histogram flat-negative at -0.23, RSI14 is 32.05 after printing 30.13 on 2026-11-11, and Williams %R is -89.63. ADX14 has risen from 12.6 to 21.05 while price fell, so trend strength is building in the DOWN direction (ADX is direction-agnostic and must be read with price below all MAs). The only constructive evidence is the higher low: 2026-11-12 low 18.86 against 2026-11-11 low 18.66 (a fresh 52-week low), plus a marginal +0.58% close at 18.97, i.e. a stabilisation attempt off a low, not a demand base. TEMA14 18.81 is the one average beneath price, confirming only that the very shortest smoothing has caught down to the tape. Bounce-only structure → technicalScore 2.
You’re looking at 2026-11-13 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

